NeoGenomics Historical Income Statement

NEO Stock

USD 17.18 0.25 1.48%

Historical analysis of NeoGenomics income statement accounts such as Total Revenue of 621.2 M can show how well NeoGenomics performed in making a profits. Evaluating NeoGenomics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of NeoGenomics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining NeoGenomics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether NeoGenomics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.

About NeoGenomics Income Statement Analysis

NeoGenomics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to NeoGenomics shareholders. The income statement also shows NeoGenomics investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

NeoGenomics Income Statement Chart

At this time, NeoGenomics' Cost Of Revenue is very stable compared to the past year. As of the 26th of November 2024, Total Operating Expenses is likely to grow to about 358.3 M, though Operating Income is likely to grow to (102.3 M).

Selling General Administrative Total Revenue Gross Profit Other Operating Expenses

Total Revenue

Total revenue comprises all receipts NeoGenomics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of NeoGenomics minus its cost of goods sold. It is profit before NeoGenomics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of NeoGenomics. It is also known as NeoGenomics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from NeoGenomics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into NeoGenomics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.At this time, NeoGenomics' Cost Of Revenue is very stable compared to the past year. As of the 26th of November 2024, Total Operating Expenses is likely to grow to about 358.3 M, though Operating Income is likely to grow to (102.3 M).

	2021	2022	2023	2024 (projected)
Interest Expense	5.1M	1.5M	6.9M	7.3M
Depreciation And Amortization	62.1M	79.2M	72.6M	76.2M

Interest Expense Depreciation And Amortization

NeoGenomics income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.51	0.99	0.96	0.92	0.99	-0.82	-0.8	-0.36	0.98	0.99	-0.83	0.37	-0.8	-0.79	0.97	0.98	-0.8	0.2	0.12	-0.74	0.73	0.84	0.92	-0.59
Interest Expense	0.51		0.53	0.64	0.68	0.57	-0.12	-0.08	0.33	0.61	0.52	-0.15	0.14	-0.12	-0.37	0.34	0.54	-0.12	-0.05	0.26	-0.27	0.72	0.46	0.25	-0.39
Selling General Administrative	0.99	0.53		0.98	0.95	1.0	-0.77	-0.75	-0.28	0.99	1.0	-0.78	0.4	-0.74	-0.77	0.95	0.99	-0.74	0.2	0.09	-0.71	0.72	0.84	0.9	-0.59
Total Revenue	0.96	0.64	0.98		0.99	0.99	-0.67	-0.65	-0.15	1.0	0.98	-0.69	0.32	-0.64	-0.78	0.88	0.99	-0.64	0.2	0.14	-0.71	0.75	0.84	0.82	-0.59
Gross Profit	0.92	0.68	0.95	0.99		0.96	-0.61	-0.58	-0.08	0.98	0.95	-0.62	0.27	-0.58	-0.73	0.83	0.97	-0.58	0.17	0.11	-0.66	0.76	0.84	0.76	-0.59
Other Operating Expenses	0.99	0.57	1.0	0.99	0.96		-0.74	-0.73	-0.25	1.0	1.0	-0.76	0.37	-0.72	-0.78	0.94	1.0	-0.72	0.21	0.12	-0.73	0.73	0.84	0.88	-0.59
Operating Income	-0.82	-0.12	-0.77	-0.67	-0.61	-0.74		0.99	0.82	-0.71	-0.77	0.99	0.0	0.99	0.62	-0.89	-0.73	0.99	-0.11	0.0	0.63	-0.65	-0.77	-0.87	0.6
Ebit	-0.8	-0.08	-0.75	-0.65	-0.58	-0.73	0.99		0.84	-0.69	-0.76	1.0	0.0	0.99	0.65	-0.87	-0.71	0.99	-0.13	-0.02	0.66	-0.57	-0.71	-0.87	0.51
Ebitda	-0.36	0.33	-0.28	-0.15	-0.08	-0.25	0.82	0.84		-0.2	-0.29	0.81	0.34	0.84	0.3	-0.49	-0.23	0.84	-0.01	0.08	0.36	-0.26	-0.37	-0.52	0.31
Cost Of Revenue	0.98	0.61	0.99	1.0	0.98	1.0	-0.71	-0.69	-0.2		0.99	-0.73	0.35	-0.68	-0.8	0.91	0.99	-0.68	0.21	0.16	-0.74	0.74	0.83	0.85	-0.58
Total Operating Expenses	0.99	0.52	1.0	0.98	0.95	1.0	-0.77	-0.76	-0.29	0.99		-0.79	0.39	-0.75	-0.77	0.96	0.99	-0.75	0.21	0.09	-0.72	0.72	0.85	0.9	-0.59
Income Before Tax	-0.83	-0.15	-0.78	-0.69	-0.62	-0.76	0.99	1.0	0.81	-0.73	-0.79		-0.01	1.0	0.67	-0.89	-0.75	1.0	-0.13	-0.03	0.67	-0.62	-0.73	-0.88	0.53
Total Other Income Expense Net	0.37	0.14	0.4	0.32	0.27	0.37	0.0	0.0	0.34	0.35	0.39	-0.01		0.01	-0.14	0.37	0.37	0.01	0.23	-0.02	-0.11	-0.01	0.11	0.37	0.0
Net Income	-0.8	-0.12	-0.74	-0.64	-0.58	-0.72	0.99	0.99	0.84	-0.68	-0.75	1.0	0.01		0.59	-0.87	-0.71	1.0	-0.11	0.04	0.59	-0.62	-0.72	-0.85	0.54
Income Tax Expense	-0.79	-0.37	-0.77	-0.78	-0.73	-0.78	0.62	0.65	0.3	-0.8	-0.77	0.67	-0.14	0.59		-0.71	-0.78	0.59	-0.28	-0.57	0.98	-0.38	-0.52	-0.73	0.28
Research Development	0.97	0.34	0.95	0.88	0.83	0.94	-0.89	-0.87	-0.49	0.91	0.96	-0.89	0.37	-0.87	-0.71		0.93	-0.87	0.2	0.0	-0.68	0.7	0.84	0.95	-0.63
Selling And Marketing Expenses	0.98	0.54	0.99	0.99	0.97	1.0	-0.73	-0.71	-0.23	0.99	0.99	-0.75	0.37	-0.71	-0.78	0.93		-0.7	0.25	0.09	-0.72	0.72	0.85	0.88	-0.59
Net Income From Continuing Ops	-0.8	-0.12	-0.74	-0.64	-0.58	-0.72	0.99	0.99	0.84	-0.68	-0.75	1.0	0.01	1.0	0.59	-0.87	-0.7		-0.11	0.04	0.59	-0.62	-0.72	-0.85	0.54
Non Recurring	0.2	-0.05	0.2	0.2	0.17	0.21	-0.11	-0.13	-0.01	0.21	0.21	-0.13	0.23	-0.11	-0.28	0.2	0.25	-0.11		0.1	-0.28	-0.13	-0.03	0.32	0.21
Non Operating Income Net Other	0.12	0.26	0.09	0.14	0.11	0.12	0.0	-0.02	0.08	0.16	0.09	-0.03	-0.02	0.04	-0.57	0.0	0.09	0.04	0.1		-0.58	-0.03	-0.07	0.05	0.03
Tax Provision	-0.74	-0.27	-0.71	-0.71	-0.66	-0.73	0.63	0.66	0.36	-0.74	-0.72	0.67	-0.11	0.59	0.98	-0.68	-0.72	0.59	-0.28	-0.58		-0.32	-0.49	-0.71	0.29
Interest Income	0.73	0.72	0.72	0.75	0.76	0.73	-0.65	-0.57	-0.26	0.74	0.72	-0.62	-0.01	-0.62	-0.38	0.7	0.72	-0.62	-0.13	-0.03	-0.32		0.89	0.6	-0.83
Net Interest Income	0.84	0.46	0.84	0.84	0.84	0.84	-0.77	-0.71	-0.37	0.83	0.85	-0.73	0.11	-0.72	-0.52	0.84	0.85	-0.72	-0.03	-0.07	-0.49	0.89		0.77	-0.87
Reconciled Depreciation	0.92	0.25	0.9	0.82	0.76	0.88	-0.87	-0.87	-0.52	0.85	0.9	-0.88	0.37	-0.85	-0.73	0.95	0.88	-0.85	0.32	0.05	-0.71	0.6	0.77		-0.47
Extraordinary Items	-0.59	-0.39	-0.59	-0.59	-0.59	-0.59	0.6	0.51	0.31	-0.58	-0.59	0.53	0.0	0.54	0.28	-0.63	-0.59	0.54	0.21	0.03	0.29	-0.83	-0.87	-0.47

Click cells to compare fundamentals

NeoGenomics Account Relationship Matchups

NeoGenomics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	30.3M	41.9M	62.1M	79.2M	72.6M	76.2M
Interest Expense	3.7M	7.0M	5.1M	1.5M	6.9M	7.3M
Selling General Administrative	128.0M	143.8M	221.3M	243.4M	243.1M	255.3M
Total Revenue	408.8M	444.4M	484.3M	509.7M	591.6M	621.2M
Gross Profit	196.8M	185.9M	187.1M	187.9M	244.6M	256.8M
Other Operating Expenses	395.8M	458.4M	603.1M	662.8M	688.3M	722.7M
Operating Income	8.4M	(2.1M)	(10.0M)	(153.1M)	(107.7M)	(102.3M)
Ebit	8.4M	(7.0M)	(10.0M)	(157.8M)	(90.2M)	(85.7M)
Ebitda	38.6M	34.9M	52.1M	(78.6M)	(17.6M)	(16.7M)
Cost Of Revenue	212.0M	258.6M	297.3M	321.8M	347.0M	364.4M
Total Operating Expenses	183.8M	199.9M	305.8M	341.0M	341.3M	358.3M
Income Before Tax	3.6M	(14.1M)	(15.1M)	(159.3M)	(97.1M)	(92.2M)
Total Other Income Expense Net	(4.7M)	(64K)	103.7M	(1.7M)	10.6M	5.9M
Net Income	8.0M	4.2M	(8.3M)	(144.3M)	(88.0M)	(83.6M)
Income Tax Expense	(4.4M)	(18.2M)	(6.7M)	(15.1M)	(9.1M)	(8.7M)
Research Development	8.5M	8.2M	21.9M	30.3M	27.3M	28.7M
Selling And Marketing Expenses	47.4M	47.9M	62.6M	67.3M	70.8M	74.4M
Net Income From Continuing Ops	8.0M	4.2M	(8.3M)	(144.3M)	(88.0M)	(83.6M)
Net Income Applicable To Common Shares	8.0M	4.2M	(8.3M)	(144.3M)	(129.8M)	(123.3M)
Non Operating Income Net Other	(5.6M)	10.5M	(499K)	(213K)	(245.0K)	(232.7K)
Tax Provision	(4.4M)	(18.2M)	(6.7M)	(15.1M)	(9.1M)	(9.6M)
Interest Income	6.2M	3.7M	3.1M	6.1M	16.9M	17.7M
Net Interest Income	(3.7M)	(7.0M)	(5.1M)	(1.5M)	10.0M	10.5M
Reconciled Depreciation	30.3M	35.7M	53.4M	69.4M	72.6M	48.0M

Pair Trading with NeoGenomics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoGenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoGenomics will appreciate offsetting losses from the drop in the long position's value.

Moving against NeoGenomics Stock

0.85	HCM	HUTCHMED DRC	Pair Corr
0.82	FLGC	Flora Growth Corp	Pair Corr
0.59	AQB	AquaBounty Technologies	Pair Corr
0.57	EXAS	EXACT Sciences Buyout Trend	Pair Corr
0.55	VRDN	Viridian Therapeutics	Pair Corr

The ability to find closely correlated positions to NeoGenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoGenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoGenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoGenomics to buy it.

The correlation of NeoGenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoGenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoGenomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for NeoGenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock:

How To Invest In NeoGenomics

Details

Is NeoGenomics Stock a good investment?

Details

What is NeoGenomics' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.

You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

1.306

Earnings Share

(0.61)

Revenue Per Share

5.098

Quarterly Revenue Growth

0.104

Return On Assets

(0.03)

The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NeoGenomics Historical Income Statement

About NeoGenomics Income Statement Analysis

NeoGenomics Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

NeoGenomics income statement Correlations

NeoGenomics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NeoGenomics income statement Accounts

Pair Trading with NeoGenomics

Moving against NeoGenomics Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Operating Expenses	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Cost Of Revenue	+ 1.0	Total Revenue
Cost Of Revenue	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Selling And Marketing Expenses	+ 1.0	Other Operating Expenses

Research Development	- 0.89	Income Before Tax
Research Development	- 0.89	Operating Income
Reconciled Depreciation	- 0.88	Income Before Tax
Extraordinary Items	- 0.87	Net Interest Income
Net Income From Continuing Ops	- 0.87	Research Development
Research Development	- 0.87	Net Income